Skip to main content

Table 1 Demographics

From: Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

 

Rituximab (n = 8)

Controls (n = 11)

Age (mean/SD)

62.3 (5.2)

63.4 (6.4)

Race (%)

  

 White

7 (87.5)

10 (90.9)

 Unknown

1 (12.5)

1 (9.1)

Ethnicity (%)

  

 Hispanic

1 (12.5)

1 (9.1)

 Non-hispanic

6 (75)

9 (81.8)

 Unknown

1 (12.5)

1 (9.1)

PSA at diagnosis (mean/SD)

7.7 (4.7)

7.5 (4.7)

Gleason risk group after prostatectomy (n/%)

  

 I (GS 3 + 3)

–

3 (27.3)a

 II (GS 3 + 4)

1 (12.5)

–

 III (GS 4 + 3)

2 (25)

–

 IV and V (GS ≥ 8)

5 (62.5)

8 (72.7)

pT stage

  

 pT2a-c

3 (37.5)

2 (18.2)

 pT3a-b

5 (62.5)

9 (81.8)

  1. aAll were pT3a